Genmab — Oktober 2016
-
other oncology stiger 36% i Q3
-
-
Strong growth in new products include IMBRUVICA
(ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; DARZALEX -
Worldwide operational results, excluding the net impact of acquisitions, divestitures and hepatitis C sales, were driven by new products and the strength of core products. Strong growth in new products include IMBRUVICA
(ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; DARZALEX (daratumumab), for the treatment of patients with multiple myeloma; and XARELTO (rivaroxaban), an oral anticoagulant. -
samlet salg omkring $400 mio for 9mdr
?? Er det ikke deromrking vi er?? -
enig
-
det er ihvertfald lang over det genmab guider med
-
langt
-
-
link til webcast J/J
-
det er jo det mønster, der har været i månedsvis. kommer der nyheder bliver der solgt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind